Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
source: by Timothy Hay
When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes.
But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has . . .
→ Read full post: Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says
The Edward Snowden controversy has highlighted how much presumed private data is actually on public wires, passing through public routers — effectively in the public domain.
The truth is, privacy in our modern society is misunderstood. In fact, true privacy is ephemeral. Thomas Jefferson probably died thinking that knowledge of his sexual relations with some of his slaves was going to die with him. How could he know that two centuries later, modern genetics showed . . .
→ Read full post: The Underside of the Cloud
Top 5 pathways to personalized medicine
Healthcare IT NewsJeff RoweJuly 22, 2013
If there’s one thing everyone in healthcare can probably agree on right now, it’s that there is an awful lot of data being generated each and every day. What to do with that data, however, is another question.
As Ted Driscoll, digital health director at venture capital firm Claremont Creek Ventures, sees it, the explosion of data is a definite boon . . .
→ Read full post: Ted Driscoll interview in Health Care IT News “Top 5 pathways to personalized medicine”
One of the toughest challenges for a startup is managing through a growth phase while still keeping an eye ahead to a strategy for the next phase. For the past few years I’ve enjoyed enlisting teams of Duke students to get out of the classroom and help company’s in our portfolio with a bit of market discovery. This year’s team just finished a project with Blue Pillar and described . . .
→ Read full post: The importance of getting out of the classroom
The human genome evolved for us as Paleolithic cavemen, arming us to cope with leopards, communicable diseases, infections, parasites and starvation. But modern society has succeeded in taming most of those risks, and now, ironically, our biggest health challenges are largely a byproduct of our success. As we extend our lifespan, cancer and cardiac disease increase in incidence. We confront an epidemic of diabetes and obesity related diseases largely caused by overconsumption and inactivity. Our genome never evolved to benefit obese 70 year olds. Cavemen didn’t typically live past 40 and didn’t drink high-fructose corn syrup in Big Gulps. . . .
→ Read full post: The Golden Age of Healthcare Investing is Now
November 28, 2012. Source: Nobel Profit
Listen to venture capitalist Nat Goldhaber, managing director of Claremont Creek Ventures, share his insights around energy and policy in California in regards to clean tech investments. In this interview he focuses on a particular investment in solar with Clean Power Finance as it relates to the public utilities and our indigenous production as a relief from foreign oil, a strategy he sees as vitally important to . . .
→ Read full post: Nat Goldhaber video interview with Nobel Profit
An energy-independent United States is an achievable goal by 2025, according to new research commissioned by Claremont Creek Ventures. In order to achieve this audacious goal, the United States needs to clear an important set of hurdles. . . .
→ Read full post: Claremont Creek Ventures Predicts Energy Independence By 2025
I was struck recently by a piece in The Wall Street Journal by Pui-Wing Tam, The $1 Billion Club Gets Crowded, which highlights the amusing rate at which closely held, private US companies in the social media sector are garnering $1 billion-plus valuations. With 20 companies already fetching a 10-figure price tag— 15 of them since the beginning of last year— the bubble has swelled quickly. Even during the dot-com boom of . . .
→ Read full post: Me-too, In-Fashion Investing Fueling A Social Media Bubble
On March 20, 2012, the Lester Center for Entrepreneurship proudly recognized biotech pioneer Moshe Alafi with its 2012 Lifetime Achievement Award at a special awards dinner. A Berkeley alumnus, Mr. Alafi is one of the founders of the biotechnology industry. He has funded and helped start over 60 companies through his venture capital firm Alafi Capital. Many of these firms have created entire new industries including such pioneers as Cetus, Biogen, Applied Biosystems, and Amgen. His life is an incredible inspiration to entrepreneurs as a successful investor and startup partner as well as one who has done an incredible amount to improve our health and scientific knowledge with biotechnology breakthroughs. . . .
→ Read full post: Moshe Alafi wins Lifetime Achievement Award — videos of event